Italia -
italiano -
Ministero della Salute
tylovet 1g/g granulato per soluzione orale
huvepharma nv - tilosina tartrato - tilosina tartrato - 1.1 grammo (i), tylosina tartrato - 1.1 g - tylosin
Italia -
italiano -
Ministero della Salute
supratil
fatro s.p.a. - tilosina - tilosina - 200 milligrammo (i), tilosina - 200 mg - tylosin
Italia -
italiano -
Ministero della Salute
oxylan
qalian italia s.r.l. - tilosina, ossitetraciclina - tilosina - 100 g; ossitetraciclina - 200 g - tetracyclines, combinations with other antibacterials
Italia -
italiano -
Ministero della Salute
furazolidone 2% + ossitetraciclina 2% formevet
formevet s.r.l. - ossitetraciclina, furazolidone. - ossitetraciclina - nd ; furazolidone. - nd - tetracyclines, combinations with other antibacterials
Italia -
italiano -
Ministero della Salute
tylan 200
elanco gmbh - tilosina - tilosina - 200 milligrammo (i), tilosina - 200 mg - tylosin
Italia -
italiano -
Ministero della Salute
ossitetraciclina 50% trei
industria italiana integratori trei s.p.a. - ossitetraciclina - ossitetraciclina - 500 grammo (i), ossitetraciclina - 500 g - oxytetracycline
Unión Europea -
italiano -
EMA (European Medicines Agency)
tukysa
seagen b.v. - tucatinib - breast neoplasms; neoplasm metastasis - agenti antineoplastici - tukysa is indicated in combination with trastuzumab and capecitabine for the treatment of adult patients with her2‑positive locally advanced or metastatic breast cancer who have received at least 2 prior anti‑her2 treatment regimens.
Unión Europea -
italiano -
EMA (European Medicines Agency)
locametz
novartis europharm limited - gozetotide - imaging dei radionuclidi - radiofarmaci diagnostici - questo medicinale è solo per uso diagnostico. locametz, after radiolabelling with gallium 68, is indicated for the detection of prostate specific membrane antigen (psma) positive lesions with positron emission tomography (pet) in adults with prostate cancer (pca) in the following clinical settings:primary staging of patients with high risk pca prior to primary curative therapy,suspected pca recurrence in patients with increasing levels of serum prostate specific antigen (psa) after primary curative therapy,identification of patients with psma positive progressive metastatic castration resistant prostate cancer (mcrpc) for whom psma targeted therapy is indicated (see section 4.